Molecular similarity considerations in the licensing of orphan drugs
The large costs associated with modern drug discovery mean that governments and regulatory bodies need to provide economic incentives to promote the development of orphan drugs, i.e., of medicinal products that are designed to treat rare disease that affect only small numbers of patients. Under EU legislation a medicine can only be authorised for treating a specific rare disease if it is not similar to other orphan drugs already authorised for that particular disease. This paper discusses the use of 2D fingerprints to calculate the Tanimoto similarity between potential and existing orphan drugs for the same disease, and presents logistic regression models correlating these computed similarities with the judgements of human experts.
views in local repository
downloads in local repository
The information is available from the following content providers: